实用药物与临床
實用藥物與臨床
실용약물여림상
Practical Pharmacy and Clinical Remedies
2015年
10期
1199-1201
,共3页
江乐%俞国峰%张亦婷%陆地
江樂%俞國峰%張亦婷%陸地
강악%유국봉%장역정%륙지
广泛耐药鲍曼不动杆菌%ICU%耐药性%治疗对策
廣汎耐藥鮑曼不動桿菌%ICU%耐藥性%治療對策
엄범내약포만불동간균%ICU%내약성%치료대책
Extensively drug resistant acinetobacter baumannii.%ICU%Drug resistance%Treatment strategy
目的 研究ICU肺炎患者感染广泛耐药鲍曼不动杆菌的耐药性并给出治疗对策. 方法 选取我院ICU病房30例广泛耐药鲍曼不动杆菌性肺炎患者作为研究组,30例非广泛耐药鲍曼不动杆菌肺炎患者作为对照组,分析两组患者治疗指标与感染广泛耐药鲍曼不动杆菌的影响,分别采集患者的菌株并进行耐药性试验,评估广泛耐药鲍曼不动杆菌的耐药性并制定治疗对策. 结果 研究组与对照组患者的合并基础疾病个数、感染前住院时间、SOFA评分、GCS评分、抗菌药物治疗天数、侵入治疗天数等指标比较差异均有统计学意义( P<0. 05);研究组与对照组菌株耐药性除对多粘菌素B、多粘菌素E外差异均有统计学意义(P<0. 05). 结论 广泛耐药鲍曼不动杆菌性肺炎与合并基础疾病、抗菌药物使用天数、侵入治疗等有关,其对常用抗菌药物均有显著耐药性,应以多种抗菌药物联用治疗.
目的 研究ICU肺炎患者感染廣汎耐藥鮑曼不動桿菌的耐藥性併給齣治療對策. 方法 選取我院ICU病房30例廣汎耐藥鮑曼不動桿菌性肺炎患者作為研究組,30例非廣汎耐藥鮑曼不動桿菌肺炎患者作為對照組,分析兩組患者治療指標與感染廣汎耐藥鮑曼不動桿菌的影響,分彆採集患者的菌株併進行耐藥性試驗,評估廣汎耐藥鮑曼不動桿菌的耐藥性併製定治療對策. 結果 研究組與對照組患者的閤併基礎疾病箇數、感染前住院時間、SOFA評分、GCS評分、抗菌藥物治療天數、侵入治療天數等指標比較差異均有統計學意義( P<0. 05);研究組與對照組菌株耐藥性除對多粘菌素B、多粘菌素E外差異均有統計學意義(P<0. 05). 結論 廣汎耐藥鮑曼不動桿菌性肺炎與閤併基礎疾病、抗菌藥物使用天數、侵入治療等有關,其對常用抗菌藥物均有顯著耐藥性,應以多種抗菌藥物聯用治療.
목적 연구ICU폐염환자감염엄범내약포만불동간균적내약성병급출치료대책. 방법 선취아원ICU병방30례엄범내약포만불동간균성폐염환자작위연구조,30례비엄범내약포만불동간균폐염환자작위대조조,분석량조환자치료지표여감염엄범내약포만불동간균적영향,분별채집환자적균주병진행내약성시험,평고엄범내약포만불동간균적내약성병제정치료대책. 결과 연구조여대조조환자적합병기출질병개수、감염전주원시간、SOFA평분、GCS평분、항균약물치료천수、침입치료천수등지표비교차이균유통계학의의( P<0. 05);연구조여대조조균주내약성제대다점균소B、다점균소E외차이균유통계학의의(P<0. 05). 결론 엄범내약포만불동간균성폐염여합병기출질병、항균약물사용천수、침입치료등유관,기대상용항균약물균유현저내약성,응이다충항균약물련용치료.
Objective To study the drug resistance of ICU patients infected by extensively drug resistant acin-etobacter baumannii.( XDRAB) and formulate the treatment strategy. Methods Thirty ICU patients of hospital-ac-quired pneumonia due to XDRAB in our hospital were selected as the research group,meanwhile 30 cases pneumonia patients without the infection of XDRAB was chosen as control group. Biochemical indicators of the two groups and in-fluence on the infection of XDRAB were analyzed. Bacterial strains of patients were respectively collected and drug re-sistance tests were performed. Drug resistance to XDRAB was evaluated and corresponding treatment strategy was pres-ented. Results Significant differences were found between the two groups in the indicators such as the number of co-existed underlying diseases,hospitalization time before the infection,SOFA assessment,GCS assessment,treatment days after using antibiotic and the invasion (P<0. 05);there were significant differences in the drug resistance between the two groups except polymyxin B and polymyxin E ( P<0. 05 ) . Conclusion XDRAB is implicated in the number of co-existed underlying diseases,treatment days after using antibiotic and after the invasion. Obvious drug resistance to the common antibiotics can be found and combination treatment with various antibiotics should be taken.